BACKGROUND: The study rationale was to compare the biomarker profile of metalloproteinases (MMPs) and inflammation markers (IMs) in patients requiring revascularization with that of patients with long-term, clinically quiescent coronary artery disease (CAD). METHODS: Seventy-eight patients with symptomatic CAD (S-CAD) (7 patients with myocardial infarction and 71 patients with stable angina) and 67 patients with asymptomatic CAD (A-CAD) were enrolled. Plasma samples were analyzed for MMPs, MMP inhibitors (MMPIs), IMs, coagulation factors, and apolipoproteins by use of the fluorokine multianalyte profiling assay. RESULTS: Patients with S-CAD had markedly elevated levels of specific MMPs (MMP-2, MMP-9), MMPIs (alpha2-macroglobulin, tissue inhibitor of MMP 1), IMs (C-reactive protein; interleukin [IL] 8; IL-10, regulated upon activation, normal T-cell expressed and secreted [RANTES], endothelin, plasminogen activator inhibitor 1, and apolipoprotein C-III compared with patients with A-CAD (P < .005 for all measurements), whereas patients with A-CAD had significantly greater levels of MMP-3 and IL-1alpha compared with patients with S-CAD (P < or = .02 for both measurements). CONCLUSIONS: A specific profile of MMPs, IMs, and other biomarkers distinguishes the patient with progressive coronary atherosclerosis culminating in either elective or emergent percutaneous coronary intervention from the patient with quiescent disease. The early implementation of a biomarker analysis may identify the patient at risk for plaque progression and refine the definition of "stable" angina.
BACKGROUND: The study rationale was to compare the biomarker profile of metalloproteinases (MMPs) and inflammation markers (IMs) in patients requiring revascularization with that of patients with long-term, clinically quiescent coronary artery disease (CAD). METHODS: Seventy-eight patients with symptomatic CAD (S-CAD) (7 patients with myocardial infarction and 71 patients with stable angina) and 67 patients with asymptomatic CAD (A-CAD) were enrolled. Plasma samples were analyzed for MMPs, MMP inhibitors (MMPIs), IMs, coagulation factors, and apolipoproteins by use of the fluorokine multianalyte profiling assay. RESULTS:Patients with S-CAD had markedly elevated levels of specific MMPs (MMP-2, MMP-9), MMPIs (alpha2-macroglobulin, tissue inhibitor of MMP 1), IMs (C-reactive protein; interleukin [IL] 8; IL-10, regulated upon activation, normal T-cell expressed and secreted [RANTES], endothelin, plasminogen activator inhibitor 1, and apolipoprotein C-III compared with patients with A-CAD (P < .005 for all measurements), whereas patients with A-CAD had significantly greater levels of MMP-3 and IL-1alpha compared with patients with S-CAD (P < or = .02 for both measurements). CONCLUSIONS: A specific profile of MMPs, IMs, and other biomarkers distinguishes the patient with progressive coronary atherosclerosis culminating in either elective or emergent percutaneous coronary intervention from the patient with quiescent disease. The early implementation of a biomarker analysis may identify the patient at risk for plaque progression and refine the definition of "stable" angina.
Authors: Justin L Grodin; Tiffany M Powell-Wiley; Colby R Ayers; Darpan S Kumar; Anand Rohatgi; Amit Khera; Darren K McGuire; James A de Lemos; Sandeep R Das Journal: Vasc Med Date: 2011-10 Impact factor: 3.239
Authors: William T Hu; Alice Chen-Plotkin; Steven E Arnold; Murray Grossman; Christopher M Clark; Leslie M Shaw; Leo McCluskey; Lauren Elman; Jason Karlawish; Howard I Hurtig; Andrew Siderowf; Virginia M-Y Lee; Holly Soares; John Q Trojanowski Journal: Acta Neuropathol Date: 2010-07-22 Impact factor: 17.088
Authors: Emanuel Schwarz; Rauf Izmailov; Michael Spain; Anthony Barnes; James P Mapes; Paul C Guest; Hassan Rahmoune; Sandra Pietsch; F Markus Leweke; Matthias Rothermundt; Johann Steiner; Dagmar Koethe; Laura Kranaster; Patricia Ohrmann; Thomas Suslow; Yishai Levin; Bernhard Bogerts; Nico Jm van Beveren; George McAllister; Natalya Weber; David Niebuhr; David Cowan; Robert H Yolken; Sabine Bahn Journal: Biomark Insights Date: 2010-05-12
Authors: Daniel Martins-de-Souza; Laura W Harris; Paul C Guest; Christoph W Turck; Sabine Bahn Journal: Eur Arch Psychiatry Clin Neurosci Date: 2009-12-09 Impact factor: 5.270
Authors: Sid E O'Bryant; Stephen C Waring; Valerie Hobson; James R Hall; Carol B Moore; Teodoro Bottiglieri; Paul Massman; Ramon Diaz-Arrastia Journal: J Geriatr Psychiatry Neurol Date: 2009-11-20 Impact factor: 2.680